In a report issued on October 4, Robert Catellier from CIBC maintained a Hold rating on HEXO Corp (HEXO), with a price target of C$7.50. The company’s shares closed last Monday at $4.06.
According to TipRanks.com, Catellier is ranked #830 out of 5539 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for HEXO Corp with a $5.63 average price target.
See today’s analyst top recommended stocks >>
Based on HEXO Corp’s latest earnings release for the quarter ending April 30, the company reported a quarterly GAAP net loss of $5.82 million. In comparison, last year the company had a GAAP net loss of $8.06 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HEXO Corp. engages in the manufacture, production, and distribution of medicinal marijuana. It offers products through the Time of Day, H2, Decarb, and Exlixir No. 1 brands. The company was founded by Sébastien St. Louis and Adam Miron on August 13, 2013 and is headquartered in Gatineau, Canada.
Read More on HEXO:
